Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q2 FY2019 Earnings Presentation
8 slides from Aurobindo Pharma's earnings presentation, Nov 12, 2018
Slide 1: Q2 FY18-19 Earnings Presentation
Q2 FY18-19 EARNINGS PRESENTATION 12th November 2018
Slide 2: Disclaimer
Disclaimer This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these
Slide 3: Consolidated Financial & Business Highlights – Q2FY19
Consolidated Financial & Business Highlights – Q2FY19 Key Financial Highlights • Revenue from Operations increased by 7.1% YoY and 11.8% QoQ to INR 4,751.4 Cr, driven by healthy growth in both formulations and APIs • EBIDTA before Forex and Other income at INR 1,026.0 Cr vs INR 1,117.3 Cr in Q2FY18
Slide 4: US Filings Snapshot
US Filings Snapshot Addressable Cumulative ANDA Filings and Approvals Therapy ANDAs Market Size (US$ Bn) Anti Diabetic 19 8.7 ARV** 42 6.4 CNS 92 24.6 Controlled Substances 17 1.5 CVS 80 24.2 Gastroenterological 30 3.8 Ophthalmics 11 0.4 Others 156 15.7 Penem 2 0.5 Respiratory (inc. Nasal) 12 0.7 On
Slide 5: Consolidated Financial Performance – Q2FY19 YoY
Consolidated Financial Performance – Q2FY19 YoY Q2 Q2 % Value INR Cr Revenue from Operations - Breakup FY19 FY18 Chg Value in INR Cr Q2FY19 Q2FY18 % Chg Formulations 3,934.8 3,663.3 7.4 USA 2,226.8 2,098.9 6.1 API 816.6 771.8 5.8 EU 1,156.5 1,113.5 3.9 Formulations % of sales 82.8% 82.6% Growth mark
Slide 6: Consolidated Financial Performance – Q2FY19 QoQ
Consolidated Financial Performance – Q2FY19 QoQ Q2 Q1 % Value INR Cr Revenue from Operations - Breakup FY19 FY19 Chg Value in INR Cr Q2FY19 Q1FY19 % Chg Formulations 3,934.8 3,500.8 12.4 USA 2,226.8 1,889.6 17.8 API 816.6 748.0 9.2 EU 1,156.5 1,199.1 -3.5 Formulations % of sales 82.8% 82.4% Growth m
Slide 7: Debt Profile
Debt Profile Fx Loan US$ Mn Debt as on (INR Cr) Mar-16 Mar-17 Mar-18 Jun-18 Sep-18 Closing Rate1 US$ = 66.25 64.85 65.17 68.47 72.485 INR Fx Loan restated in 4,956.7 3,121.5 4,766.9 5,284.0 5,493.4 748 481 731 772 758 INR Rupee Loan 46.9 244.8 4.1 14.1 282.2 Sales Tax Deferment 41.9 0.0 0.0 0.0 0.0
Slide 8: Thank You
Thank You For updates and specific queries, please visit our website www. aurobindo.com Investor Relations: Phone: +91-40-66725000/5401 +91 98486 67906 Email: [email protected] Corporate Office: Water Mark Building, Level-1, Plot No.11, Survey No. 9, Kondapur, Hitech City, Hyderabad - 500084 Register